CN102899392A - miRNA set detection method and application used in colorectal cancer diagnosis - Google Patents
miRNA set detection method and application used in colorectal cancer diagnosis Download PDFInfo
- Publication number
- CN102899392A CN102899392A CN2011102130152A CN201110213015A CN102899392A CN 102899392 A CN102899392 A CN 102899392A CN 2011102130152 A CN2011102130152 A CN 2011102130152A CN 201110213015 A CN201110213015 A CN 201110213015A CN 102899392 A CN102899392 A CN 102899392A
- Authority
- CN
- China
- Prior art keywords
- mir
- biomarker
- intestinal cancer
- seq
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 32
- 238000003745 diagnosis Methods 0.000 title claims abstract description 19
- 239000002679 microRNA Substances 0.000 title claims abstract description 9
- 108091070501 miRNA Proteins 0.000 title claims abstract 8
- 206010009944 Colon cancer Diseases 0.000 title abstract description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract description 9
- 239000000090 biomarker Substances 0.000 claims abstract description 60
- 210000002966 serum Anatomy 0.000 claims abstract description 41
- 108091066091 miR-767 stem-loop Proteins 0.000 claims abstract description 31
- 108091058491 miR-877 stem-loop Proteins 0.000 claims abstract description 31
- 108091040501 miR-129 stem-loop Proteins 0.000 claims abstract description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 14
- 238000011529 RT qPCR Methods 0.000 claims abstract description 13
- 108091026822 U6 spliceosomal RNA Proteins 0.000 claims abstract description 13
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 67
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 59
- 238000011002 quantification Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 12
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000012807 PCR reagent Substances 0.000 claims description 5
- 238000007477 logistic regression Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000013016 damping Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 13
- 238000003753 real-time PCR Methods 0.000 description 10
- 108091024127 miR-634 stem-loop Proteins 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 108091058688 miR-141 stem-loop Proteins 0.000 description 2
- 108091062762 miR-21 stem-loop Proteins 0.000 description 2
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 2
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a miRNA set detection method and an application thereof used in colorectal cancer diagnosis. The set of miRNA is a set comprising miR-129-3p, miR-767-3p, and miR-877* biomarkers. The miRNA sequences are respectively represented by SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3. The detection method comprises the steps that: (1) a human blood serum sample is collected; (2) blood serum total RNA is extracted; (3) reverse transcription and real-time quantitative PCR reaction are carried out upon the biomarkers, and PCR relative quantitative values of the biomarkers are calculated with U6 snRNA as an internal reference; and (4) a P value is calculated according to relative quantitative values of the biomarkers; when P is higher than 0.6621, the sample is considered as a colorectal cancer sample; and when P is smaller than 0.6621, the sample is considered as a non-colorectal-cancer sample. With the set of biomarkers, colorectal cancer detection and diagnosis can be carried out simply and fast, such that better treatment can be promoted.
Description
Technical field
The present invention relates to a kind of little RNA of endogenous non-coding (MicroRNA, miRNA) as biomarker, particularly relate to detection method and application for one group of miRNA of intestinal cancer diagnosis.
Background technology
Large bowel cancer comprises rectum cancer and colon cancer, is one of common cancer.The West Europe such as the U.S., Canada and North America developed country are the highest countries of sickness rate, and sickness rate is up to 35～50,/10 ten thousand, and its sickness rate and case fatality rate are only second to lung cancer and occupy the 2nd in malignant tumour.The pertinent data of China shows that incidence of colorectal is 15.7/10 ten thousand populations, accounts for the 4th～6 of malignant tumour, and the trend that increases is gradually arranged.China's Colorectal Cancer number in 2005 and death toll reach respectively 17.2 ten thousand and 9.9 ten thousand, surpass the U.S..Can this sick prognosis is depended on early diagnosis and surgical radical treatment.Yet because how asymptomatic early stage large bowel cancer is, when Most patients was made a definite diagnosis, a late period, 5 years survival rates only had been 50.21% behind the large bowel cancer radical correction.Carcinomebryonic antigen (Carcinoembryonic antigen, CEA) is the large bowel cancer blood serum tumor markers of finding the earliest, but CEA all has in various degree rising in most of malignant tumour serum, and specificity is lower, and is not high to the early diagnosis value of large bowel cancer.Therefore seek desirable high specificity, tumor markers that susceptibility is high is one of important means that improves control.
MicroRNA (miRNA) is the non-coding RNA molecule that the length found in animal and plant body is about 21～25 Nucleotide, mainly suppresses to finish it to the negative regulation of target gene by cutting off degraded and translation.Because the diversity of its sequence, structure, abundance and phraseology makes it that widely effect be arranged in the eukaryotic gene expression regulation and control.As the positive participant of human tumor signal path, miRNA is not only playing the part of the role of proto-oncogene and cancer suppressor gene, and is also relevant with the transfer apoptosis of tumour.Because different tumours demonstrates specific miRNA express spectra, miRNA has very high stability in the tissue that formalin is fixed, in serum and plasma, also stable expression can be arranged so increasing scientist proposes miRNA, and can be used as potential novel tumor mark.Single miRNA can affect hundreds of protein expressions, and the length of 21-25 Nucleotide has determined that also miRNA does not have complicated structure and modification, and these characteristics have all indicated the superiority of miRNA as Biomarkers.Existing research finds that miR-141 has obvious up-regulated in comprising the epithelial cell Serum of Cancer Patients of human prostata cancer, and prompting miR-141 can be used as the Biomarkers of judging tumor type.The ovarian cancer patients that lacks obvious clinical symptom and effective Biomarkers also can detect to improve with serum miRNA the possibility of early diagnosis and early stage treatment.Scientists find and confirmed miR-21,92,93,126 and 29a obvious overexpression is arranged in the tumour serum sample, and miR-155,127 and the expression of 99b obviously reduce.The expression of miR-21 is obviously increased in this external diffuse large B cell lymphoma serum, and the miR-21 that increases has also hinted preferably without the recurrence survival rate.This result shows, the specific expressed early diagnosis that not only helps tumour of check miRNA, and the prognosis that also can be used for patient is judged.These researchs confirm fully that all the mensuration of serum and blood plasma miRNA is one and detects the up-and-coming field of carcinobiology mark.Thereby, develop a kind of miRNA biomarker of assisting intestinal cancer diagnosis, can set up a kind of more responsively, more accurate making a definite diagnosis in early days and even the method for early treatment intestinal cancer has widely scientific research value and potential applicability in clinical practice.
Summary of the invention
The technical problem to be solved in the present invention provides detection method and the application for one group of miRNA of intestinal cancer diagnosis, especially relates to one group of miRNA biomarker for detection of intestinal cancer (miR-129-3p, miR-767-3p and miR-877*), method and application thereof.Utilize this group biomarker can carry out simply, quickly the intestinal cancer diagnosis and detection, so that better treatment.
For solving the problems of the technologies described above, one group of the present invention is used for the miRNA biomarker that intestinal cancer detects, and is the respectively miR-129-3p of miRNA sequence, miR-767-3p and miR-877* shown in SEQ IDNO.1, NO.2, NO.3.This group miRNA specific expressed rise in patients with bowel cancer serum.
This group biomarker can also be applied to the diagnosis of intestinal cancer.
In addition, the present invention also provides a kind of and has utilized above-mentioned biomarker group to carry out the method that intestinal cancer detects, and specifically may further comprise the steps:
(1) collector's serum sample;
(2) extract total RNA (comprising miRNA) in the serum;
(3) miR-129-3p, miR-767-3p and miR-877* biomarker are carried out reverse transcription and real-time quantitative PCR (RT-PCR), and calculate the PCR relative quantification value of each biomarker;
(4) calculate P value (the possible probability of intestinal cancer) according to the PCR relative quantification value of each biomarker, when the P value greater than 0.6621 the time, then think the intestinal cancer sample, less than 0.6621 o'clock, then think it is non-intestinal cancer sample.
Wherein, the concrete operations of step (1) collector's serum sample are: the blood sample of collecting is put into the test tube that does not contain EDTA (ethylenediamine tetraacetic acid (EDTA)), leave standstill solidify after, get supernatant, at 4 ℃ of lower 600g～900g after centrifugal 5～15 minutes, get again supernatant and centrifugal 5～15 minutes of 4 ℃ of lower 12000g～16000g, get again supernatant and get final product.
Total RNA extracting in the step (2) can operate according to business-like RNA extraction agent box, and measures the concentration of RNA.
Reverse transcription in the step (3) can be carried out according to business-like reverse transcription test kit; RT-PCR reaction also can operate according to commercialization RT-PCR reaction kit, wherein, in the RT-PCR reaction, with U6snRNA as confidential reference items, and the primer of designed, designed U6snRNA, and use 2
-Δ CtFormula calculates the PCR relative quantification value of each biomarker, Δ Ct=Ct in the formula
Biomarker-Ct
U6, Ct is the thresholding cycle number, Ct
BiomarkerThe Ct value of each biomarker, Ct
U6It is the Ct value of U6snRNA.The reverse transcription reaction condition is: 37 ℃ 1 hour, 95 ℃ 5 minutes.The primer sequence of U6 snRNA is designed to TTCGTGAAGCGTTCCATATTTT (shown in the SEQ ID NO.4) in the RT-PCR reaction, the primer sequence of miR-129-3p biomarker is AAGCCCTTACCCCAAAAAGC (shown in the SEQ ID NO.5), the primer sequence of miR-767-3p biomarker is TCTGCTCATACCCCATGGTTTCT (shown in the SEQ ID NO.6), the primer sequence of miR-877* biomarker is TCCTCTTCTCCCTCCTCCCAG (shown in the SEQ ID NO.7), its RT-PCR reaction conditions be 95 ℃ 15 minutes, then circulate, cycling condition is: 94 ℃ 15 seconds, 55 ℃ 30 seconds, 70 ℃ 34 seconds, totally 40 circulations.
P value in the step (4) (intestinal cancer may probability) circular is: according to Logistic regression equation logit (P)=-1.4867-8.2881* (the PCR relative quantification value of miR-129-3p)+87.1459* (the PCR relative quantification value of miR-767-3p)+0.1681* (the PCR relative quantification value of miR-877*) calculates logit (P), and draws corresponding P value according to the logit (P) [with reference to table 3 (quoting from Medcalc software application guide)] of gained.
Moreover, the present invention also provides a kind of biomarker group detection kit for the intestinal cancer detection, this detection kit comprises: conventional real-time quantitative PCR reagent (comprising: Taq enzyme, dNTP reagent, fluorescent reagent, PCR damping fluid, DEPC process water etc.), the detection primer of confidential reference items U6 snRNA (shown in the SEQ ID NO.4), the detection primer of miR-129-3p, miR-767-3p, miR-877* (shown in SEQ ID NO.5, NO.6 and the NO.7).Wherein, the working method of this detection kit can be carried out with reference to the method for utilizing above-mentioned biomarker group to carry out the intestinal cancer detection.
Experimental data of the present invention shows that tumour and normal sample all have specific serum miRNA express spectra.MiR-129-3p among the present invention, miR-767-3p and miR-877* there are differences expression in normal people and patients with bowel cancer serum, significant up-regulated is arranged in intestinal cancer serum.In addition, it is that threshold value is according to concrete experimental data and statistical formula gained as the foundation of judging intestinal cancer that the P value of biomarker group among the present invention (intestinal cancer possibility probability) gets 0.6621, wherein, experimental data comprises embodiment 1 and the embodiment 2 in the following specific embodiment.Therefore, can become the effective tool that intestinal cancer detects diagnosis, pathological grading, clinical stages, the judgement for the treatment of curative effect, have good potential applicability in clinical practice.
Description of drawings
The present invention is further detailed explanation below in conjunction with accompanying drawing and embodiment:
Fig. 1 is normal serum sample among the embodiment 2 and the miR-129-3p in the intestinal cancer serum sample (Fig. 1-A), miR-767-3p (Fig. 1-B), miR-877* (Fig. 1-C) and the miR-634 (comparison diagram of gene expression abundance (case figure) of Fig. 1-D), wherein, ordinate zou is the PCR relative quantification value of each biomarker;
Fig. 2 judges biomarker miR-129-3p (Fig. 2-A), miR-767-3p (Fig. 2-B), miR-877* (Fig. 2-C) and the miR-634 (diagnostic value in the intestinal cancer sample (ROC graphic representation) of Fig. 2-D) according to ROC curve (receiver operating characteristic curve, recipient's operating characteristic curve) among the embodiment 2;
Fig. 3 judges the diagnostic value (ROC graphic representation) of biomarker group in the intestinal cancer sample according to the ROC curve among the embodiment 2.
Embodiment
The foundation of the miRNA biomarker combinations that the intestinal cancer that is used for embodiment 1 detects
1. collection serum sample
Gather 10 normal peoples, 7 front peripheral blood 2mL (blood sampling time is generally morning or the morning) of the different stadium patient of colorectal cancer patients art, wherein, the concrete clinical data of these 17 serum samples is as shown in table 1.The 2mL peripheral blood that gathers is changed over to rapidly in the common test tube that does not contain EDTA, leave standstill 15～30 minutes to solidifying fully 22～25 ℃ (room temperatures).Get 0.6ml～1mL supernatant and go in the clean 1.5mL centrifuge tube, at 1 hour (under the room temperature condition) or carried out following operation in 2 hours in (under 4 ℃ of conditions): centrifugal 10 minutes of 4 ℃ of lower 820g; Again draw supernatant and go in the clean 1.5mL centrifuge tube, centrifugal 10 minutes of 4 ℃ of lower 16000g carefully draw supernatant in new centrifuge tube, place-80 ℃ to save backup.
The concrete clinical data of table 117 serum sample
2. total RNA (comprising miRNA) extracting in the serum
Every increment is originally got 400 μ L serum, uses the mirVana of Applied Biosystem company
TMPARIS
TMTest kit, step extracted total RNA to specifications, and get 1 μ LRNA, use NanoDrop ND-1000 Spectrophotometer instrument by specification step to measure RNA concentration and be placed on-80 ℃ of preservations.
3. gene chip hybridization
Get the serum RNA of 100ng institute extracting, use the miRNA Complete Labeling and Hyb test kit of Agilent Technologies company, step is carried out sample labeling and concentrated to specifications, uses the people microRNA chip of expression spectrum of Agilent Technologies company to hybridize.Use chip scanner to carry out after the image scanning, data importing GeneSpring GX11.0 software is carried out the standardization of data and follow-up analysis, the valid data after the chip normalization method are used Pearson correlation carry out cluster analysis.
4. data analysis and checking
Chip data analysis finds that the sample and the normal sample that derive from colorectal cancer are all assembled together separately, the sample that prompting serum miRNA express spectra can distinguishing different.Utilize the information biology means such as multiple analysis, t check, cluster analysis to carry out differential genes expression analysis, seek possible differential gene, and further with the real-time quantitative PCR checking, finishing screen is selected 4 miRNA---miR-129-3p, miR-634, miR-767-3p and the miR-877* of specific expressed rise in intestinal cancer.
Embodiment 2 applying biological mark groups are carried out the method that intestinal cancer detects
1. collection serum sample
Gather the front peripheral blood 2mL of art of 24 routine onset colorectal cancer patients, and mate 18 routine normal people's blood samples originally, the clinical data of 42 routine serum samples is as shown in table 2.Operate according to " collection serum sample " step among the embodiment 1, but centrifugal condition wherein changes into: centrifugal 15 minutes of 4 ℃ of lower 600g; Again draw supernatant and go in the clean 1.5mL centrifuge tube, centrifugal 15 minutes of 4 ℃ of lower 12000g carefully draw supernatant in new centrifuge tube, and the serum that obtains at last saves backup in-80 ℃.
The concrete clinical data of table 242 serum sample
2. total RNA (comprising miRNA) extracting in the serum
As operating according to embodiment 1.
3. reverse transcription and Real time-PCR (RT-PCR) reaction
The RNA that gets the extracting of 60ng institute uses the miScript Reverse Transcription reverse transcription test kit of Qiagen company to carry out reverse transcription reaction.20 μ L reaction systems: the RNA+Rnase free water that 60ng extracts (summation of RNA and Rnase free water is 15 μ L), 5 * miScript RT Buffer, 4 μ L, miScript Reverse Transcriptase Mix 1 μ L.Carry out reverse transcription reaction at thermal cycler, reaction conditions is as follows: 37 ℃ 1 hour, 95 ℃ 5 minutes.
Get the reverse transcription product of 1.5 μ L as the template of real-time quantitative PCR reaction, use the miScript SYBR Green PCR test kit of Qiagen company to carry out the real-time quantitative PCR reaction.Quantitative PCR is take U6 snRNA as confidential reference items, and designs the primer of these confidential reference items.20 μ L reaction systems: 1.5 μ L reverse transcription products, 2 * QuantiTect SYBR Green PCR Master Mix, 10 μ L, 10 * miScript Universal Primer, 2 μ L, the Auele Specific Primer of each biomarker or confidential reference items U6 snRNA (concentration is 20 μ M) 2 μ L, Rnase free water 4.5 μ L.The primer sequence of miR-129-3p is shown in the SEQ ID NO.5, the primer sequence of miR-767-3p is shown in the SEQ ID NO.6, the primer sequence of miR-877* is shown in the SEQ ID NO.7, the primer sequence of miR-634 is shown in the SEQ ID NO.8 (AACCAGCACCCCAACTTTG), and the primer sequence of U6 snRNA is shown in the SEQ ID NO.4.Reaction is carried out at 7300 quantitative PCR instrument of Applied Biosystem company, and condition is 95 ℃ of preheatings 15 minutes, then circulates, and cycling condition is: 94 ℃ 15 seconds, 55 ℃ 30 seconds, 70 ℃ 34 seconds, the PCR of totally 40 circulations reaction.
The PCR relative quantification of each biomarker uses 2
-Δ CtFormula calculates, wherein Δ Ct=Ct
Biomarker-Ct
U6The result shows the miR-129-3p in the intestinal cancer serum sample, and miR-767-3p, the expression amount of miR-877* and miR-634 all obviously raise.The PCR relative quantification value of the average miR-129-3p of intestinal cancer is 0.29, and the PCR relative quantification value of the average miR-129-3p of normal sample only is 0.068, and difference has significance (p=0.019).The PCR relative quantification value of the average miR-767-3p of intestinal cancer is 0.038, and the PCR relative quantification value of the average miR-767-3p of normal sample only is 0.0054, and difference has significance (p=0.00067).The PCR relative quantification value of the average miR-877* of intestinal cancer is 28.90, and the PCR relative quantification value of the average miR-877* of normal sample only is 3.19, and difference has significance (p=0.0018).The PCR relative quantification value of the average miR-634 of intestinal cancer is 0.040, and the PCR relative quantification value of the average miR-634 of normal sample only is 0.0087, and difference has significance (p=0.0070) (Fig. 1).Find when further judging the diagnostic value of each biomarker in the intestinal cancer sample according to the ROC curve, susceptibility when alone serum miR-129-3p relative quantification value (greater than 0.12) is carried out the intestinal cancer diagnosis is 62.5%, specificity is 88.89%, and the AUC area that can produce the ROC curve is 0.796; Susceptibility when alone miR-767-3p relative quantification value (greater than 0.011) is carried out the intestinal cancer diagnosis is 62.5%, and specificity is 83.33%, and the AUC area that can produce the ROC curve is 0.803; Susceptibility when alone serum miR-877* relative quantification value (greater than 7.63) is carried out the intestinal cancer diagnosis is 70.83%, and specificity is 88.89%, and the AUC area that can produce the ROC curve is 0.836; Susceptibility when alone serum miR-634 relative quantification value (greater than 0.011) is carried out the intestinal cancer diagnosis is 75%, and specificity is 70.59%, and the AUC area that can produce the ROC curve is 0.752 (Fig. 2).More than the AUC area that produces of each independent biomarker all more than 0.7, point out these 4 biomarkers as the Case definition of intestinal cancer certain accuracy to be arranged all separately.
4. with miR-129-3p, miR-767-3p and miR-877* are as the biomarker group of intestinal cancer detection
Take above-mentioned 4 biomarkers as the basis, further use step logistic regression to screen best biomarker combinations, to obtain optimal diagnosis effect.Regression Analysis Result shows, use miR-129-3p, the ROC tracing analysis is carried out in the combination of miR-767-3p and miR-877* can obtain best AUC area (area under the curve, area under curve) (AUC=0.868), increase miR-634 and can not promote diagnostic value, thereby the final biomarker (Fig. 3) of determining that use miR-129-3p, miR-767-3p and miR-877* detect as intestinal cancer.
Calculate P value (the possible probability of intestinal cancer) according to the PCR relative quantification value of miR-129-3p, miR-767-3p and miR-877*: at first according to Logistic regression equation: logit (P)=-1.4867-8.2881* (the PCR relative quantification value of miR-129-3p)+87.1459* (the PCR relative quantification value of miR-767-3p)+0.1681* (the PCR relative quantification value of miR-877*) calculates logit (P), then draws corresponding P value with reference to table 3 (quoting from Medcalc software application guide).When the P value greater than 0.6621 the time, then think the intestinal cancer sample, less than 0.6621 o'clock, then think it is non-intestinal cancer sample.According to the ROC tracing analysis, when the P value greater than 0.6621 the time, the susceptibility when miR-129-3p, miR-767-3p and miR-877* biomarker combinations carry out the intestinal cancer diagnosis is 66.7%, specificity is 100%.
The corresponding table with the P value of table 3logit (p) value
Embodiment 3 detection kit and application
The miR-129-3p that is used for the intestinal cancer detection in the present embodiment, miR-767-3p and miR-877* biomarker group detection kit, except containing conventional real-time quantitative PCR reagent, the detection primer (shown in the SEQ ID NO.4) and the miR-129-3p that also comprise confidential reference items U6 snRNA, the detection primer of miR-767-3p and miR-877* (SEQ ID NO.5 is shown in NO.6 and the NO.7).Wherein, conventional real-time quantitative PCR reagent comprises that Taq enzyme, dNTP reagent, fluorescent reagent, PCR damping fluid, DEPC (diethylpyrocarbonate) process water (Rnase free water).
When utilizing above-mentioned detection kit to detect, its concrete working method can be carried out the detection of sample and the judgement of intestinal cancer with reference to the working method of embodiment 2, wherein, the centrifugal condition in " collection serum sample " step can also be centrifugal 5 minutes of 4 ℃ of lower 900g; Again draw supernatant and go in the clean 1.5mL centrifuge tube, centrifugal 5 minutes of 4 ℃ of lower 16000g.
The detection kit of using in the present embodiment can be carried out the detection of biomarker group simply, fast, expediently, to judge the intestinal cancer situation, is convenient to treatment.
Sequence table
Claims (10)
1. one group is used for the miRNA biomarker that intestinal cancer detects, and it is characterized in that: described miRNA biomarker is respectively miR-129-3p, miR-767-3p and the miR-877* of miRNA sequence shown in SEQ ID NO.1, NO.2, NO.3.
2. the miRNA biomarker for the intestinal cancer detection as claimed in claim 1 is characterized in that: described miR-129-3p, miR-767-3p and the miR-877* specific expressed rise in patients with bowel cancer serum.
3. miR-129-3p as claimed in claim 1 or 2, miR-767-3p and miR-877* biomarker also are applied to the diagnosis of intestinal cancer.
4. the confidential reference items during the real-time quantitative PCR that is applied to the biomarker group as claimed in claim 1 reacts, it is characterized in that: described confidential reference items are U6snRNA, its primer sequence is shown in SEQ ID NO.4.
5. the biomarker group of utilizing as claimed in claim 1 is carried out the method that intestinal cancer detects, and comprises step:
(1) collector's serum sample;
(2) extract total RNA in the serum;
(3) to miR-129-3p, miR-767-3p and miR-877* biomarker carry out reverse transcription and real-time quantitative PCR reaction, and calculate the PCR relative quantification value of each biomarker;
(4) calculating intestinal cancer according to the PCR relative quantification value of each biomarker may the probability P value, when the P value greater than 0.6621 the time, then think the intestinal cancer sample, less than 0.6621 o'clock, then think it is non-intestinal cancer sample.
6. the biomarker group of utilizing as claimed in claim 5 is carried out the method that intestinal cancer detects, it is characterized in that: the concrete operations of described step (1) collector's serum sample are: the human blood sample of collecting is put into the test tube that does not contain EDTA, leave standstill solidify after, get supernatant at 4 ℃ of lower 600g～900g after centrifugal 5～15 minutes, get again supernatant, and centrifugal 5～15 minutes of 4 ℃ of lower 12000g～16000g, get supernatant and get final product.
7. the biomarker group of utilizing as claimed in claim 5 is carried out the method that intestinal cancer detects, it is characterized in that: in the real-time quantitative PCR reaction in the described step (3), with U6snRNA as confidential reference items, the primer sequence of these confidential reference items is shown in SEQ ID NO.4, and the primer sequence of miR-129-3p, miR-767-3p and miR-877* biomarker group is respectively shown in SEQ ID NO.5, NO.6 and NO.7; And use 2
-Δ CtFormula calculates the PCR relative quantification value of each biomarker, Δ Ct=Ct in the formula
Biomarker-Ct
U6
8. the biomarker group of utilizing as claimed in claim 5 is carried out the method that intestinal cancer detects, it is characterized in that: intestinal cancer in the described step (4) may probability P value circular be: according to Logistic regression equation logit (P)=-1.4867-8.2881* (the PCR relative quantification value of miR-129-3p)+87.1459* (the PCR relative quantification value of miR-767-3p)+0.1681* (the PCR relative quantification value of miR-877*), calculate logit (P), and draw corresponding P value according to the logit (P) of gained.
9. the biomarker group detection kit that detects for intestinal cancer as claimed in claim 1, it is characterized in that: described detection kit comprises: conventional real-time quantitative PCR reagent, the detection primer of confidential reference items U6 snRNA shown in SEQ ID NO.4, respectively the detection primer of miR-129-3p, the miR-767-3p shown in SEQ ID NO.5, NO.6, NO.7 and miR-877* biomarker.
10. the biomarker group detection kit that detects for intestinal cancer as claimed in claim 9, it is characterized in that: described conventional real-time quantitative PCR reagent comprises: Taq enzyme, dNTP reagent, fluorescent reagent, PCR damping fluid, DEPC process water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102130152A CN102899392A (en) | 2011-07-28 | 2011-07-28 | miRNA set detection method and application used in colorectal cancer diagnosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102130152A CN102899392A (en) | 2011-07-28 | 2011-07-28 | miRNA set detection method and application used in colorectal cancer diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102899392A true CN102899392A (en) | 2013-01-30 |
Family
ID=47571879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102130152A Pending CN102899392A (en) | 2011-07-28 | 2011-07-28 | miRNA set detection method and application used in colorectal cancer diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102899392A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103882129A (en) * | 2014-03-19 | 2014-06-25 | 江苏大学 | Fluorescent quantitative PCR (polymerase chain reaction) method and kit for detecting miR-9 in human plasmas |
| CN107557467A (en) * | 2017-08-10 | 2018-01-09 | 李永东 | A kind of clinical marker thing related to cerebral aneurysm and its application |
| CN109852686A (en) * | 2019-02-26 | 2019-06-07 | 浙江大学医学院附属妇产科医院 | The internal reference collection of excretion body miRNA a kind of and more internal reference combination with standard sizing techniques |
| CN114317743A (en) * | 2021-12-23 | 2022-04-12 | 广西百谷生物科技有限公司 | miRNA detection kit for colorectal cancer prognosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101657547A (en) * | 2006-07-13 | 2010-02-24 | 俄亥俄州立大学研究基金会 | MicroRNA-based methods and compositions for diagnosis and treatment of colon cancer-related diseases |
| WO2011076142A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
-
2011
- 2011-07-28 CN CN2011102130152A patent/CN102899392A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101657547A (en) * | 2006-07-13 | 2010-02-24 | 俄亥俄州立大学研究基金会 | MicroRNA-based methods and compositions for diagnosis and treatment of colon cancer-related diseases |
| WO2011076142A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
Non-Patent Citations (3)
| Title |
|---|
| JESSICA A. WEBER ET AL.: "The MicroRNA Spectrum in 12 Body Fluids", 《CLINICAL CHEMISTRY》, vol. 56, no. 11, 30 November 2010 (2010-11-30), pages 1735 - 2, XP055188106, DOI: doi:10.1373/clinchem.2010.147405 * |
| SHUYANG WANG ET AL.: "Improvement of tissue preparation for laser capture microdissection: application for cell", 《BMC GENOMICS》, vol. 11, no. 163, 31 December 2010 (2010-12-31), pages 1471 - 2164 * |
| 林茂松: "人结直肠癌microRNA表达谱及其临床意义的研究", 《中国博士学位论文全文数据库》, 26 September 2010 (2010-09-26), pages 1 - 90 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103882129A (en) * | 2014-03-19 | 2014-06-25 | 江苏大学 | Fluorescent quantitative PCR (polymerase chain reaction) method and kit for detecting miR-9 in human plasmas |
| CN107557467A (en) * | 2017-08-10 | 2018-01-09 | 李永东 | A kind of clinical marker thing related to cerebral aneurysm and its application |
| CN107557467B (en) * | 2017-08-10 | 2021-05-11 | 李永东 | Clinical marker related to cerebral aneurysm and application thereof |
| CN109852686A (en) * | 2019-02-26 | 2019-06-07 | 浙江大学医学院附属妇产科医院 | The internal reference collection of excretion body miRNA a kind of and more internal reference combination with standard sizing techniques |
| CN114317743A (en) * | 2021-12-23 | 2022-04-12 | 广西百谷生物科技有限公司 | miRNA detection kit for colorectal cancer prognosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105018594B (en) | A kind of colorectal cancer early diagnosis marker and related kit | |
| CN111961725B (en) | Kit or device for detecting pancreatic cancer and detection method | |
| CN109797219B (en) | Application of reagent for detecting ABRACL expression level and kit | |
| CN107043823A (en) | A kind of related tumor markers of colorectal cancer and application | |
| WO2009119809A1 (en) | Marker for determination of breast cancer, test method, and test kit | |
| CN105018638A (en) | Detection and application of gastric carcinogenesis associated molecular marker IncRNA (long non-coding RNA) HOTTIP (HOXA transcript at the distal tip) | |
| CN102899392A (en) | miRNA set detection method and application used in colorectal cancer diagnosis | |
| CN106119392A (en) | A kind of serum miRNA marker relevant to esophageal squamous cell carcinoma auxiliary diagnosis and application thereof | |
| Chu et al. | The potential of circulating exosomal RNA biomarkers in cancer | |
| Kural et al. | Urinary extracellular vesicles-encapsulated miRNA signatures: A new paradigm for urinary bladder cancer diagnosis and classification | |
| Ghanbari et al. | Expression Analysis of Previously Verified Fecal and Plasma Down-regulated MicroRNAs (miR-4478, 1295-3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients. | |
| CN102605042A (en) | Application of miR-378 biomarker in detection and diagnosis of gastric cancer | |
| Nakajima et al. | Ribonucleic acid microarray analysis from lymph node samples obtained by endobronchial ultrasonography-guided transbronchial needle aspiration | |
| CN105219841A (en) | The detection kit of a kind of lung cancer differential expression microRNA and application thereof | |
| WO2010004562A2 (en) | Methods and compositions for detecting colorectal cancer | |
| CN109576266B (en) | Marker and kit for predicting sensitivity of HER2 positive metastatic breast cancer patient to trastuzumab | |
| EP3473729A1 (en) | Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method | |
| CN101555520A (en) | Has-mir-122 kit for early prediction of hepatocirrhosis developed from chronic hepatitis B and detection method thereof | |
| CN112553341A (en) | Kidney clear cell carcinoma SCNN1 primer, diagnosis kit and application thereof | |
| CN107586844A (en) | Application of glioma prognostic marker Circ9:135881633|135883078 | |
| CN107619869B (en) | Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application | |
| CN107746886B (en) | A plasma miRNA marker related to auxiliary diagnosis of colorectal cancer and its application | |
| CN107858424B (en) | Application of miRNA-4731-3p as a diagnostic marker for primary lung cancer | |
| CN116377074A (en) | Application of miR-15a-5p in early diagnosis and prognosis evaluation of oral squamous cell carcinoma | |
| CN107460251A (en) | A kind of the glioblastoma auxiliary diagnosis based on FUCA1 genes, prognostic evaluation kit and its application method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130130 |